Posted by Michael Wonder on 30 Jan 2016
Allergan's rapastinel receives FDA breakthrough therapy designation for adjunctive treatment of major depressive disorder
29 January 2016 - This follows the fast track designation for rapastinel granted by the FDA in 2014.
For more details, go to: http://www.allergan.com/news/news/thomson-reuters/allergan-s-rapastinel-receives-fda-breakthrough-th
